Impacto cardiovascular secundario a la terapia para el control del cáncer
Cardiovascular diseases and cancer account for 27 and 25% of mortality in Chile, respectively. In the last decades, survival of people with cancer has improved due to preventive programs, early detection strategies, advances in technology and development of new antineoplastic therapies. Consequently...
Guardado en:
Autores principales: | Ríos,Juvenal A., Rojo,Pamela, Schuster,AndréS, Gormaz,Juan G., Carrasco,Rodrigo, Neira,Carolina, Becerra,Sergio, Labbé,Tomas P. |
---|---|
Lenguaje: | Spanish / Castilian |
Publicado: |
Sociedad Médica de Santiago
2020
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000100093 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Assesment of the TEI index of myocardial performance in dogs with doxorubicin-induced cardiomiopathy
por: Sousa,MG, et al.
Publicado: (2014) -
Genetic basis of anthracyclines cardiotoxicity: Literature review
por: M. Yu. Sinitsky, et al.
Publicado: (2021) -
<i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients
por: Alejandro Velasco-Ruiz, et al.
Publicado: (2021) -
Assessment of Myocardial Work in Cancer Therapy-Related Cardiac Dysfunction and Analysis of CTRCD Prediction by Echocardiography
por: Jingyuan Guan, et al.
Publicado: (2021) -
Cardiotoxicidad inducida por tratamientos oncológicos. Fundamentos para la implementación de equipos de Cardio-Oncología
por: Hameau,René, et al.
Publicado: (2018)